A randomized trial tested a new migraine medication. After 12 weeks, monthly migraine days dropped as follows: placebo, -0.4; low dose, -1.2; medium dose, -3.8; high dose, -3.9. The researchers argued that the drug provides clear benefit at the medium dose but no further gain at higher doses. The data most uniquely supporting "no further gain at higher doses" is ______
Which choice most logically completes the text using the data above?
- Acheck_circle
the near-identical drops at medium (-3.8) and high doses (-3.9).
- B
the low dose drop of -1.2.
- C
the placebo group's -0.4 drop.
- D
the difference between placebo and high dose.
Explanation
"No further gain beyond medium dose" requires showing the high dose adds essentially nothing over the medium dose. Choice B captures this flat comparison (-3.8 vs. -3.9).